Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

Bioethicists call for stronger oversight of direct-to-consumer neurotechnologies

Bioethi­cists call for over­sight of poor­ly reg­u­lat­ed, con­sumer-grade neu­rotech­nol­o­gy prod­ucts (Med­ical News):

The mar­ket­ing of direct-to-con­sumer “neu­rotech­nolo­gies” can be entic­ing: apps that diag­nose a men­tal state, and brain devices that improve cog­ni­tion or “read” one’s emo­tion­al state. How­ev­er, many of these increas­ing­ly pop­u­lar prod­ucts aren’t ful­ly sup­port­ed by sci­ence and have lit­tle to no reg­u­la­to­ry over­sight, which pos­es poten­tial health risks to the pub­lic. In a new piece pub­lished in the jour­nal Sci­ence this week, two bioethi­cists from Penn Med­i­cine and the Uni­ver­si­ty of British Colum­bia sug­gest the cre­ation of a work­ing group that would fur­ther study, mon­i­tor, and pro­vide guid­ance for this grow­ing indus­try — which is expect­ed to top $3 bil­lion by 2020.

“There’s a real thirst for knowl­edge about the effi­ca­cy of these prod­ucts from the pub­lic, which remains unclear because of this lack of over­sight and gap in knowl­edge,” said lead author Anna Wexler, PhD, an instruc­tor in the depart­ment of Med­ical Ethics and Health Pol­i­cy at the Perel­man School of Med­i­cine at the Uni­ver­si­ty of Penn­syl­va­nia. “We believe a diverse, ded­i­cat­ed group would help back up or refute claims made by com­pa­nies, deter­mine what’s safe, bet­ter under­stand their use among con­sumers, and address pos­si­ble eth­i­cal con­cerns.”

The Paper

Over­sight of direct-to-con­sumer neu­rotech­nolo­gies (Sci­ence):

Sum­ma­ry: Mar­ket­ed for the pur­pose of mod­u­lat­ing cog­ni­tion or a vari­ety of affec­tive and men­tal states, a grow­ing ecosys­tem of neu­rotech­nol­o­gy prod­ucts is being sold direct to con­sumers (DTC) with­out neces­si­tat­ing the physi­cian as inter­me­di­ary. Offer­ing indi­vid­u­als the prospect of mon­i­tor­ing and manip­u­lat­ing a range of brain func­tions from mem­o­ry to men­tal health, the major prod­uct cat­e­gories are neu­romon­i­tor­ing devices, cog­ni­tive train­ing appli­ca­tions, neu­rostim­u­la­tion devices, and men­tal health apps. The mar­ket for these prod­ucts is pre­dict­ed to top $3 bil­lion by 2020 (1). Yet there are good rea­sons to con­clude that reg­u­la­to­ry over­sight of DTC neu­rotech­nolo­gies is insuf­fi­cient. We sug­gest ways to pro­vide sys­tem­at­ic sup­port for reg­u­la­to­ry agen­cies, fund­ing bod­ies, and a pub­lic that is thirsty for knowl­edge about the effi­ca­cy of DTC neu­rotech­nol­o­gy prod­ucts.

News in Context

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness, Peak Performance, Technology

Tags: , , , , ,

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters,  SharpBrains is an independent market research firm tracking how brain science can improve our health and our lives.

Search in our archives

Follow us and Engage via…

twitter_logo_header
RSS Feed

Watch All Recordings Now (40+ Speakers, 12+ Hours)